Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis

Figure 2

Natalizumab effect ex vivo. Isolated CD4⁺ T cells from untreated (control) or natalizumab treated PBMCs were stained for CD49d expression and processed for miR-17 expression quantification (RRMS, 𝑛=2; HV, 𝑛=1). (a) (Left panel) Representative FACS dot plots of CD4 and CD49d surface expression in cells from a HV. (Right panel) Percentage of CD49d hi cells among CD4⁺ T cell populations. Bars represent mean with SEM (standard error of the mean) in three independent experiments; (RRMS, 𝑛=2; HV, 𝑛=1). (b) Percentage of inhibition of miR-17 expression and CD49d hi staining in natalizumab treated cells. Paired 𝑡-test was applied.^∗𝑃<0.05.

(a)

(b)